On Sept. 13, 2018, the Food and Drug Administration approved moxetumomab pasudotox-tdfk (LUMOXITITM, AstraZeneca Pharmaceuticals LP), a CD22-directed cytotoxin indicated for adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
The American Society of Clinical Oncology (ASCO) today issued a set of recommendations for overcoming financial barriers to patient participation in cancer clinical trials. ASCO’s policy statement, “Addressing Financial Barriers to Patient Participation in Clinical Trials,” stresses the importance of increasing participation in clinical research, especially for patients from particular ethnic/racial, geographic, age, socioeconomic, and other underserved demographic subgroups.
The number of international practices certified in delivering high-quality cancer care based on rigorous standards established by ASCO is increasing. The Medisprof Cancer Center in Romania joins six other practices in Brazil, Greece, and Spain in achieving ASCO’s Quality Oncology Practice Initiative (QOPI®) Certification.
On September 28 from 2–3 p.m. (ET), the National Cancer Institute’s Behavioral Research Program will host a free webinar, “Alcohol and Cancer in the United States,” that will feature ASCO expert Noelle K. LoConte, MD.
The American Society of Clinical Oncology (ASCO) warns that certain provisions of the 2019 Medicare Physician Fee Schedule (MPFS) proposed rule will undermine access to cancer care for Medicare beneficiaries through a combination of payment reductions under the MPFS. In a detailed comment letter to the Centers for Medicare & Medicaid Services (CMS), ASCO fully outlines its concerns with the proposal and recommends specific steps be taken to ensure changes proposed in the rule do not endanger Medicare beneficiary access to cancer care.
CancerLinQ LLC, a wholly owned nonprofit subsidiary ASCO, has announced that Stanford Health Care has signed an agreement to participate in the CancerLinQ® platform. Stanford Health Care includes Stanford Cancer Institute which is designated as a Comprehensive Cancer Center by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).
ASCO leaders recently met with representatives from the Trump Administration to discuss the delivery of high-quality, high-value cancer care as the Administration implements its “blueprint to lower drug prices and reduce out-of-pocket costs.”
Senator John McCain will lie in state in the U.S. Capitol Building today. The following ASCO statement pays tribute to his life-long service to our country.
A new Quality in Action study in the Journal of Oncology Practice (JOP) outlines a successful effort to improve appointment scheduling for patients participating in clinical trials. The methodology of this project can be utilized to evaluate and optimize other processes and units within cancer centers outside of scheduling.
In a new position statement, the American Society of Clinical Oncology (ASCO) warns that some of the practices of pharmacy benefit manager (PBM) companies use could hinder patient access to timely, high-quality cancer care. ASCO describes a range of PBM practices that, while they may be intended to help control costs in cancer care, might compromise physicians’ ability to provide the right treatment at the right time for people with cancer.
Final scores and performance feedback are now available on the Quality Payment Program website for clinicians who participated in the Merit-based Incentive Payment System (MIPS) in 2017. Participants will see a payment adjustment in 2019 based on their final 2017 score. A positive, negative, or neutral payment adjustment will be applied to the Medicare paid amount for covered professional services furnished under the Medicare Physician Fee Schedule in 2019.
In a new ASCO in Action Podcast, Edward Balaban, DO, FACP, FASCO, an ASCO delegate to the American Medical Association (AMA) House of Delegates (HOD); and Kristina Novick, MD, an ASCO alternate delegate to the AMA HOD join ASCO CEO Dr. Clifford A. Hudis to discuss the society’s role within and the importance of the AMA HOD.
CancerLinQ LLC announced today that Integra Connect’s EHR Solution for Oncology has been recognized as the first CancerLinQ® Certified Electronic Health Record (EHR) System. CancerLinQ LLC is a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO) that oversees the development and operation of CancerLinQ®, a health information technology platform working to improve quality and value of care for all patients by connecting cancer care team members, researchers, and sponsors with real-world cancer data. In addition, CancerLinQ and Integra Connect have entered into an agreement to collaborate on products and services geared toward improving the quality of cancer care and the access of the CancerLinQ® platform to oncology practices.
As of August 2018, 100 teams from oncology practices around the U.S. and the world have participated in ASCO’s Quality Training Program.
CancerLinQ LLC, a wholly-owned nonprofit subsidiary of the ASCO, has brought on technology collaborators Concerto HealthAI and Tempus to accelerate its joint research effort with the Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) aimed at understanding the real-world use, tolerability, and effectiveness of immune checkpoint inhibitors. Concerto HealthAI and Tempus have begun to assist in the analysis of a de-identified data set that CancerLinQ has provided to the FDA, representing more than 10,000 patients who have been treated with immune checkpoint inhibitors for both approved and unapproved indications.